HARBIN GLORIA PHARMACEUTICALS Co (002437) Fair Value & Analysis

Healthcare · CN · Market cap 5.9B CNY

A solid business, but screening 30% overvalued on our models.

What matters now

• Solid but not exceptional quality (69/100) and above fair value, neither a clear bargain nor a standout compounder.
• A fairly wide model range (¥1.53 to ¥3.59) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.

How to read this chart

60‑month range ¥1.68 – ¥4.04 · fair‑value band ¥1.53 – ¥3.59 · the ¥3.12 price screens above the ¥2.18 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

HARBIN GLORIA PHARMACEUTICALS Co (002437) currently trades at ¥3.12, while our model-based Fair Value estimate is ¥2.18, implying the stock looks roughly 30.1% overvalued today. The Quality Score stands at 69/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, HARBIN GLORIA PHARMACEUTICALS Co generated revenue of 2.1B CNY at a net margin of 19.4%. Revenue declined 2.2% year over year. It earns a return on equity of 19.1%. The balance sheet holds a net cash position of 480M CNY. Fundamentals as of Jul 22, 2026

Our scenario range runs from ¥1.53 (bear case) to ¥3.59 (bull case); at ¥3.12, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 24% below its 52-week high and 20% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -30%, 002437 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Growth Earnings (¥2.97) versus Dividend Discount (¥0.0100). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

HARBIN GLORIA PHARMACEUTICALS Co., LTD engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. Its products include cardiovascular and cerebrovascular, musculoskeletal, vitamins, electrolyte, diabetes-lowering, analgesics, digestive system and metabolism, anti-infective, and anti-tumor drugs.

Full company description

HARBIN GLORIA PHARMACEUTICALS Co., LTD engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. Its products include cardiovascular and cerebrovascular, musculoskeletal, vitamins, electrolyte, diabetes-lowering, analgesics, digestive system and metabolism, anti-infective, and anti-tumor drugs. Harbin Gloria Pharmaceuticals Co., Ltd was founded in 2000 and is based in Harbin, the People's Republic of China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

HARBIN GLORIA PHARMACEUTICALS Co reported revenue of ¥2.1B in FY2025 versus ¥3.1B in FY2021, a compound −9.2%/yr. Reported net income was ¥377M in FY2025, compounding +70.1%/yr from FY2021.

002437 screens 30% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →

Peer Group

Drug Manufacturers - Specialty & Generic · 626 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.